Nelkarmi Wins Accelerated FDA Approval for ALK-Positive Lung Cancer That Progressed After Alectinib or Two Earlier Drugs

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for advanced ALK-positive lung cancer after prior treatments. Approval based on trial data showing tumor shrinkage in 49% (alectinib-only) and 32% (multiple treatments). GSK acquired developer Nuvalent. Confirmatory trial required for continued approval.

Original reporting
Published Nov 18, 2026, 9:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nelkarmi Wins Accelerated FDA Approval for ALK-Positive Lung Cancer That Progressed After Alectinib or Two Earlier Drugs — source image
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

The article frames the approval as response-rate driven (not yet survival benefit) and highlights confirmatory-trial dependence, plus liver enzyme elevation as the main safety concern.

02

Market read

Traders can reassess oncology pipeline value and confirmatory-trial risk for the sponsor and developer following a new FDA approval with quantified response and safety data.

03

What to watch

Safety burden (notably ALT elevations) and the lack of disclosed pricing could limit uptake and near-term revenue expectations despite the regulatory win.

Relevance 7/10Novelty 8/10Timing: FDA accelerated approval announced Nov. 17, ahead of the Nov. 27 FDA target date.

Background

The FDA granted accelerated approval to neladalkib (Nelkarmi) for adults with advanced ALK-positive non-small cell lung cancer that progressed after earlier targeted treatment, based on ALKOVE-1 tumor response.

Company-level read

Ticker impact

$GSKBullishMedium confidence
Context

GSK announced FDA accelerated approval of Nelkarmi (neladalkib), adding a new ALK-positive lung cancer option ahead of the FDA target date.

Expected impact

Likely modest-to-positive reaction as the market incorporates a new regulatory asset, with caution around confirmatory trial outcomes.

Evidence & confidence

The piece provides the approval scope, trial basis (ALKOVE-1), and key safety signals, but does not include pricing or sales guidance, limiting magnitude certainty.

Market effects

Reinforces investor focus on ALK-positive NSCLC targeted therapies and the market’s willingness to reward accelerated approvals tied to tumor response.

Primarily impacts US-listed biotech and large-cap pharma sentiment tied to FDA oncology approvals.

Supports global oncology M&A and licensing expectations around ALK inhibitors, especially those with brain-penetration claims.

Counterpoint

Because this is accelerated approval based on tumor shrinkage without overall survival data, the market may fade the initial optimism if confirmatory trial signals are weaker.

Key entities

  • Nelkarmi (neladalkib)

    ALK-selective therapy for advanced ALK-positive NSCLC, approved under accelerated approval.

  • ALKOVE-1

    Single-arm Phase 1/2 trial supporting the accelerated approval.

  • GSK

    Announced the FDA accelerated approval and acquired Nuvalent.

  • Nuvalent

    Developed neladalkib (Nelkarmi) and is now part of GSK.

  • FDA

    Granted accelerated approval and set a confirmatory requirement for continued indication.

Related articles

$GSKMed

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

$GSKMed

GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.